Takeaways from AI for Good Innovation Summit in Partnership with DC Tech & Venture Coalition (DCTAV)

“AI can ease the burden, but the final decisions still need a human touch”

-Adam Colborn, JD, Associate Vice President, Congressional Affairs

Last week, over 450 health and technology leaders convened in a packed DC conference center for a morning summit on the present and future of Artificial Intelligence (AI) hosted by the DC Tech & Venture Coalition (DCTAV), a coalition of executives, entrepreneurs, and investors dedicated to improving the District of Columbia’s role as a hub of technology and capital. AMCP was a sponsor of the event to help spotlight responsible, patient-centered applications of AI in health care and facilitate collaboration between innovators and policymakers.

Amid forward-reaching conversations on AI’s role in defense and governance, AMCP Associate Vice President of Government Affairs Adam Colborn, JD, joined Aditi Charnoubi, Managing Partner, Tysons Advisory and Marius Linguraru, Principal Investigator and Director of the Pediatric Accelerated Intelligence Lab, Children’s National Hospital to discuss the real-world implications of AI in health care. Colborn shared how AI is already reshaping health equity, diagnostics, and access to care, and emphasized that AMCP is committed to ensuring AI’s implementation across pharmacy practice and policy is ethically sound and strategically aligned.

That commitment, Colborn explained, is especially important now, as AI’s rapid adoption across industries has outpaced or actively antagonized the regulatory frameworks meant to guide its use. While many present were eager to delegate their decision-making and information processing to AI, he cautioned that health care already offers clear examples of what can go wrong when human oversight is lacking.  

Key Takeaways

• AMCP co-hosted the AI for Good Innovation Summit with DC Tech & Venture Coalition, drawing over 450 leaders in health and technology.
• Adam Colborn, JD, AMCP’s AVP of Government Affairs, spoke on the real-world impact of AI on health equity, diagnostics, and care access.
• Regulatory concerns are growing: The "One, Big, Beautiful Bill Act" could block state AI safeguards that prevent bias and protect patients.
• Human oversight remains essential: Colborn warned against over-reliance on AI in health care decisions.
• AI has promising use cases in resource allocation, actuarial analysis, and prescription digital therapeutics (PDTs) for mental health.
• AMCP is actively shaping AI policy through standards, advocacy, and member engagement to ensure ethical, patient-centered use.
• Opportunities to get involved include the Pharmacy Policy Summit and AMCP’s AI SIG.

As Colborn noted, the One, Big, Beautiful Bill Act recently passed by the House poses a major threat to state-level AI laws that protect equity in care. By imposing a 10-year bar on state and local governments enforcing “any law or regulation” concerning AI, it has the potential to eliminate existing guardrails that ensure care is provided without bias or prejudice.  

These guidelines are essential to ensure that claims are processed appropriately without delays in care. We’ve seen AI unduly deny claims before, and Colborn stressed that regulation is key to preventing that kind of outcome from happening again. While sweeping changes to regulation may appear innovative and cost-effective, their intended effects are often outweighed by unintended consequences, such as disruptions to state protections or increased patient risk. The authors may be envisioning an eventual arms race of innovation, but before that happens, they must reckon with the need to protect public health.

However, Colborn made clear that when AI is used as an asset rather than as an arbiter, it displays incredible potential for assistance in resource optimization and allocation. Actuarial analysis, for example, shows promise with AI-driven modeling, helping us understand the downstream economic impact of pharmaceutical interventions by analyzing data in a holistic way impossible for a human being, allowing for improved cost-benefit analyses and triage.  

He also highlighted the rise of AI-enabled prescription digital therapeutics (PDTs), particularly in mental health, as a scalable and affordable option for at-home care. AMCP is developing clear standards, practical tools, and trusted insights to expand coverage of PDTs, and the current 119th Congress has supported our efforts with the introduction of the Access to PDTs ACT of 2025. This act is the epitome of how AI can make care more accessible, and we are proud to see its progress in Congress. 

AI holds potential, but we must lead with values, protect patients, and use technology to empower decision-making, not replace it.  

See how AMCP is shaping the implementation of AI

Be a part of upcoming pharmacy policy and join us at Pharmacy Policy Summit, National Harbor, MD

Shape the future of AI in managed care through our AI Special Interest Group (SIG), where discussions like these continue year-round (Link coming soon!)

View Our Corporate opportunities